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basis for exploring the macroevolutionary
history of Earth and the origin ofspecies.
Finally, all these elements are nicely syn-
thesized in a particularly readable chapter
on human evolution and both our unique-
ness from and our similarity to other
species.Abriefrecap ofsomemajorareas of
active research precedes two appendices,
one ofwhich adopts the "frequently asked
questions" modelto provide auseful primer
to those readers still confused on primary
points ofthe text.
Editing problems are evident from the
beginning,andtheirfrequencythroughoutthe
book is easily the most frustrating andpre-
ventable flaw in hatEvolutionIs. Entirely
redundant sentences and even paragraphs
are littered throughout most sections, exacer-
batingtheconfusionproducedbythealready
confusing organization ofmany chapters.
Mayr's ambitious attempts to coverall
aspects of evolution create a more under-
standable problem. While zoologists may
enjoyreading atextwith abias toward ani-
mals,those interested inotherkingdomswill
be fiustratedbythe superficial treatment of
the evolution ofplants andmicrobes. What
statements do address these topics are often
imprecise and written with an uncertainty
that sharply contrasts Mayr's confident
descriptions ofmost topics. Ofcourse, this
only proves the difficulty of any one per-
son, regardless of their experience in the
field, writing with equal knowledge and
confidence on all aspects ofa mature sci-
ence, but a book with such an ambitious
title puts exactlythis burden on the author.
Although Mayr lists creationists and evo-
lutionary agnostics as target audiences of
this essay, I doubt many members ofeither
group will find themselves convinced by
the presentation of evidence here. Mayr
himselfis so convinced ofevolution, andso
steeped inthe evidence forit, thathe seems
unable orunwillingtoaddress itsacceptance
from the position ofan outsider. Although
Mayr's logical presentation ofevidence is
at all times sound and well-reasoned, his
seemingly compulsive use of jargon and
extreme confidence may lead many read-
ers outside ofbiology to dismiss this work
as dogmatism. Non-scientists accustomed
to the plurality ofviewpoints contrasted in
works ofscientific journalism, or the con-
troversial speculation and philosophy of
manypopular science books, may find little
to holdtheirattention inthe first few chap-
ters ofthis work, which follow more ofa
textbook style. Biologists will find much
ofinterest here, but anyone with a serious
interest in evolution as a scientific enter-
prise would find the comprehensiveness of
a textbook or a few reviews plucked from
the primary literature more to their liking.
Jeremy Draghi
Yale University
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Since the first tentative and faltering
steps were taken inthe late 1970s andearly
1980s, attempts to bring successful gene
therapy treatments to humans have been rid-
dled with failure. The past few years have
beenparticularlydisappointing forthis field.
In 1999, the death of a young man in a
clinicaltrialusingadenovirustotreat aliver
disease brought abarrage ofnegative pub-
licity and impacted the progress of many
other trials underway. Most recently, the
only successful treatment, using retrovirus
vectors to treat SCID (severe combined
immunodeficiency) sufferedamajorsetback
when it was discovered that two patients
had contracted leukemia. These and other
setbacks have causedresearchers to rethink
some of the strategies used in designing
vectors. In VectorTargetingfor Therapeutic
Gene Delivery, the editors, DavidT. Curiel
and Joanne T. Douglas have sought to
compile a book dedicated to gene therapy
research that focuses on vector targeting.
The editors point out that many ofthe lim-Book reviews 333
itations encountered in gene therapy, such
as low gene expression, difficulties in pro-
ducing adequate vector amounts, immune
responses caused by non-specific trans-
duction, and non-specific gene integration
could be overcome by improving vector
targeting. The bulk of the book (Parts 1
and 2) is dedicated to articles about trans-
ductional targeting strategies, meaning
ways to design or manipulate vectors that
can deliver therapeutic genes to specific
cell types or tissues.
There are articles that describeresearch
on commonly known viral vectors like
adenovirus, AAV (adeno-associatedvirus),
and retrovirus as well as sections dedicat-
ed to viruses less commonly thought ofas
vectors, including bacteriophage and the
measles virus. The book also explains
researchonnon-viral vectors, such as lipo-
somes or lipidic vectors that have safety
benefits but often have lower transduction
efficiency. The third part of the book
focuses on transcriptional targeting, which
are attempts to ensure that therapeutic
genes are expressed only in the desired
cells. This strategyholds the mostpromise
intreatingcancer, sincecancerous cellshave
signals that can be exploited to specifically
targetthemfordestruction. Thelasttwoparts
ofthebooklookatways to identifyligands
that can be used for cell-specific gene
deliveryand awayto monitorgene expres-
sion using positron emission tomography.
Though the book is, well, targeted on
principles oftargeting,themanyarticlesalso
provide good background on every aspect
ofgene therapy research. Since designing
targetedvectors isdependentonadeepunder-
standing ofthe vector being manipulated,
the target cell, and the complex interac-
tions that occur, the articles spend a large
amount oftime explaining all these areas.
Also, the book provides a very nice broad
survey of the field of gene therapy and
makesagoodup-to-date resource inallareas
ofthis field. What I most appreciated was
the opportunity to learn about clever and
interesting strategies that receive little
attention in the mainstream press. For
example, one article describes the use ofa
Clostridium species to deliver genes that
can cause cell death to tumor cells. This
Clostridium species is anaerobic and non-
pathogenic andspecificallycolonizes hypoxic
andnecrotic areas oftissue. Becausehypoxic
and necrotic areas are unique to tumors
and not found in healthy cells, this vector
system may be able to specifically target
cancerous tumors for destruction.
Because the book is a compilation of
articles writtenbymany researchers in their
areas of expertise, the writing styles and
clarity vary greatly from chaptertochapter.
There are somepassages though, thatshow
some nice written flourishes. Forexample,
Isabella Saggio, writing on the design of
bacteriophage vectors, concludes, "It could
be speculated that a suitable gene transfer
vectorcouldbeobtainedcombiningthebest
from different worlds: theworld ofeukary-
otic viruses, that ofbacteriophage, andthat
of human fantasy." Most ofthese articles
do end on notes ofoptimism andhope that
all this work being pursued will lead to
better gene therapy strategies and eventu-
ally to success in clinical trials. For one
thing, there is no shortage of intellectual
effortandscientific researchbeing devoted
toavastarray ofsubjects inthe fieldofgene
therapy. Having read through the tremen-
dous amount of work being done just to
improve targeting in gene therapy, I can't
help feeling a little optimistic too.
Irvin L. Pan
Yale University
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The nature of the human experience
has oftenbeen conceptualized interms ofthe
mind's understanding ofthe worldthrough
the bodies interaction with it, defined in